Literature DB >> 11246552

Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP.

M G Rolf1, C A Brearley, M P Mahaut-Smith.   

Abstract

Simultaneous measurements of [Ca2+]i and light transmission were used to examine the relationship between P2X1 receptor activation and functional platelet responses. The P2X1 agonist alpha,beta-MeATP evoked a transient [Ca2+]i increase and a reversible decrease in light transmission; both responses required external Ca2+ and the nucleotidase apyrase. The transmission response was due to shape change only, verified by scanning electron microscopy and insensitivity to Reopro, a GPIIbIIIa antagonist. Alpha,beta-MeATP stimulated smaller shape changes than ADP, however P2X1 responses had a lifespan of <2 h following resuspension in saline and may be considerably larger in vivo. A peak [Ca2+]i increase of >50 nM was required for detectable shape change. Overlap of concentration-response relationships for alpha,beta-MeATP-evoked [Ca2+]i and shape change suggests that other second messengers are not involved. Therefore, the physiological P2X1 agonist ATP can contribute to platelet activation, in contrast to its previously described inhibitory action at metabotropic platelet purinoceptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246552

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  29 in total

1.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

Review 2.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

3.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

Review 4.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

5.  Molecular defects of the platelet P2 receptors.

Authors:  Marco Cattaneo
Journal:  Purinergic Signal       Date:  2011-01-29       Impact factor: 3.765

Review 6.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

Review 7.  Identification, characterization, and inhibition of the platelet ADP receptors.

Authors:  C Gachet
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

8.  P2 receptors and platelet function.

Authors:  Béatrice Hechler; Christian Gachet
Journal:  Purinergic Signal       Date:  2011-07-27       Impact factor: 3.765

9.  Kv1.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count.

Authors:  Conor McCloskey; Sarah Jones; Stefan Amisten; Roger T Snowden; Leonard K Kaczmarek; David Erlinge; Alison H Goodall; Ian D Forsythe; Martyn P Mahaut-Smith
Journal:  J Physiol       Date:  2010-03-22       Impact factor: 5.182

10.  Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors.

Authors:  Hung Chang; Ivan B Yanachkov; Alan D Michelson; YouFu Li; M R Barnard; George E Wright; Andrew L Frelinger
Journal:  Thromb Res       Date:  2009-11-27       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.